Christopher Exley

Comment on "the biological behaviour and bioavailability of aluminium in man" by N. D. Priest, JEM, 2004, 6, 375.

Christopher Exley, C. Exley, 2005, Journal of environmental monitoring : JEM.

Copper prevents amyloid-β1–42 from forming amyloid fibrils under near-physiological conditions in vitro

Christopher Exley, C. Exley, Matthew Mold, 2013, Scientific Reports.

The immunobiology of aluminium adjuvants: how do they really work?

Christopher Exley, P. Siesjö, C. Exley, 2010, Trends in immunology.

Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease.

Christopher Exley, Anthony Polwart, Peter Crome, 2012, Journal of Alzheimer's disease : JAD.

Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy

Christopher Exley, C. Exley, 2014, Allergy, Asthma & Clinical Immunology.

A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.

Christopher Exley, F. Authier, C. Exley, 2009, Medical hypotheses.

Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease.

Christopher Exley, Guy Berthon, J. Collingwood, 2004, Journal of Alzheimer's disease : JAD.

Peer review versus editorial review and their role in innovative science

Bettina Neunteufl, Mike Morris, Michael Hajek, 2012, Theoretical medicine and bioethics.